← All indications
Leukemia, Myelomonocytic, Acute
A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.
Drugs by status
Approved for this indication (1)
Phase 3 trials (22)
Phase 2 trials (28)
- azacitidine
- vitamin d3
- methylprednisolone
- lenalidomide
- trisalicylate choline
- eltrombopag
- entinostat
- gemtuzumab ozogamicin
- tacrolimus
- ixazomib
- mk-8776
- msk-2206
- omacetaxine
- pravastatin
- carboplatin
- ruxolitinib
- sirolimus
- arsenic trioxide
- mycophenolate
- bevacizumab
- topotecan
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- vorinostat
- xiap antisense
- erlotinib
- mitoxantrone
- alvocidib
Phase 1 trials (16)
Other trials (3)
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (45)
- Incyte
- Ambit Biosciences
- Celgene
- OSI Pharmaceuticals
- Aegera Therapeutics
- Genentech
- Genzyme
- Novartis
- Teva
- TetraLogic Pharmaceuticals
- Stemline Therapeutics, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Nordic MDS Group
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Case Western Reserve University
- Cornell University
- Harvard University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Hospital Avicenne
- Indiana University
- Johns Hopkins University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- Thomas Jefferson University
- University of Florence
- University of Rochester
- University of South Florida
- University of Southern California
- +15 more
Organization Involved with Phase 1 Indications (16)
- Eisai
- Amgen
- CTI BioPharma
- GlaxoSmithKline
- Northwestern University
- Ohio State University
- University of Maryland
- University of Alberta
- Wake Forest University
- Columbia University
- University of Chicago
- Jiao Tong University
- Washington University in St. Louis
- The Leukemia and Lymphoma Society
- Alex's Lemonade Stand Foundation
- Humanigen